← 產業報告目錄
Radiopharmaceutical CDMO/CMO Services Market Size, Share & Trends Analysis Distribution (Application (Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals), Type of Radioisotope (Technetium-99m, Fluorine-18, Leutetium-177, Gallium-68, Actinium-225 and Other Radioisotopes), Source of Manufacturing (Nuclear Reactors and Cyclotrons), Scale of Operation (Preclinical, Clinical and Commercial), Therapeutic Area (Cardiovascular Disorders, Neurological Disorders, Oncological Disorders and Other Disorders) and Segment Forecasts, 2025-2034
出版商 InsightAce Analytic產業別 Healthcare & Life Sciences出版日期 2026-03-15頁數 180報告編號 INSIGHTACE-f7695632a8
授權報價
| Single User PDF | $4,500 USD |
| Global Site License PDF | $9,500 USD |
報告摘要
Valued at USD 2.9 Billion as of 2024, the global Radiopharmaceutical CDMO/CMO Services Market is expected to climb to USD 7.0 Billion by 2034, reflecting a compound annual growth rate of 9.2% over the 2025–2034 period.
Radiopharmaceutical CDMO/CMO Services covers pivotal in both diagnosing and treating medical conditions. Rapid advancements and evolving end-user preferences are reshaping how healthcare entities approach this space.
Growth is bolstered by a convergence of factors: rising awareness among end users, continuous product innovation, and the rising emphasis on efficiency and sustainability within the healthcare sector.
The market landscape is structured across several key segments—spanning type, application, distribution channel, and region—each contributing uniquely to overall market expansion.
Geographically, North America maintains a leading position owing to advanced infrastructure, high R&D expenditure, and a well-established regulatory environment. Meanwhile, Asia-Pacific is emerging as the fastest-growing region, bolstered by rapid industrialization and expanding end-user bases.
Competition in this space is characterized by active product development, strategic collaborations, and geographic expansion among both global leaders and specialized niche players.
Through rigorous analysis of market trends, growth catalysts, restraints, and opportunities, this study offers valuable perspectives for companies, investors, and policymakers navigating this evolving landscape.
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Radiopharmaceutical CDMO/CMO Services Market Snapshot
Chapter 4. Global Radiopharmaceutical CDMO/CMO Services Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Porter's Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
Chapter 5. Market Segmentation 1: By Manufacturing Source Estimates & Trend Analysis
5.1. By Manufacturing Source & Market Share, 2024 & 2034
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Manufacturing Source:
5.2.1. Nuclear Reactors
5.2.2. Cyclotrons
Chapter 6. Market Segmentation 2: By Manufacturing Source Estimates & Trend Analysis
6.1. By Application & Market Share, 2024 & 2034
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Application:
6.2.1. Diagnostic Radiopharmaceuticals
6.2.1.1. Positron Emission Tomography Radiopharmaceuticals
6.2.1.2. SPECT Radiopharmaceuticals
6.2.2. Therapeutic Radiopharmaceuticals
6.2.2.1. Alpha Emitters
6.2.2.2. Beta Emitters
6.2.2.3. Other Therapeutic Radiopharmaceuticals
Chapter 7. Market Segmentation 3: By Operation Scale Estimates & Trend Analysis
7.1. By Operation Scale & Market Share, 2024 & 2034
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Operation Scale:
7.2.1. Preclinical
7.2.2. Clinical
7.2.3. Commercial
Chapter 8. Market Segmentation 4: By Radioisotope Estimates & Trend Analysis
8.1. By Radioisotope & Market Share, 2024 & 2034
8.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Radioisotope:
8.2.1. Technetium-99m
8.2.2. Fluorine-18
8.2.3. Leutetium-177
8.2.4. Gallium-68
8.2.5. Actinium-225
8.2.6. Other Radioisotopes
Chapter 9. Market Segmentation 5: By Therapeutic Area Estimates & Trend Analysis
9.1. By Therapeutic Area & Market Share, 2024 & 2034
9.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Therapeutic Area:
9.2.1. Cardiovascular Disorders
9.2.2. Neurological Disorders
9.2.3. Oncology
9.2.4. Other Therapeutic Area
Chapter 10. Radiopharmaceutical CDMO/CMO Services Market Segmentation 6: Regional Estimates & Trend Analysis
10.1. North America
10.1.1. North America Radiopharmaceutical CDMO/CMO Services Market revenue (US$ Million) estimates and forecasts By Manufacturing Source, 2021-2034
10.1.2. North America Radiopharmaceutical CDMO/CMO Services Market revenue (US$ Million) estimates and forecasts By Application, 2021-2034
10.1.3. North America Radiopharmaceutical CDMO/CMO Services Market revenue (US$ Million) estimates and forecasts By Operation Scale, 2021-2034
10.1.4. North America Radiopharmaceutical CDMO/CMO Services Market revenue (US$ Million) estimates and forecasts By Radioisotope, 2021-2034
10.1.5. North America Radiopharmaceutical CDMO/CMO Services Market revenue (US$ Million) estimates and forecasts By Therapeutic Area, 2021-2034
10.1.6. North America Radiopharmaceutical CDMO/CMO Services Market revenue (US$ Million) estimates and forecasts by Country, 2021-2034
10.1.6.1. U.S.
10.1.6.2. Canada
10.2. Europe
10.2.1. Europe Radiopharmaceutical CDMO/CMO Services Market revenue (US$ Million) estimates and forecasts By Manufacturing Source, 2021-2034
10.2.2. Europe Radiopharmaceutical CDMO/CMO Services Market revenue (US$ Million) estimates and forecasts By Application, 2021-2034
10.2.3. Europe Radiopharmaceutical CDMO/CMO Services Market revenue (US$ Million) estimates and forecasts By Operation Scale, 2021-2034
10.2.4. Europe Radiopharmaceutical CDMO/CMO Services Market revenue (US$ Million) estimates and forecasts By Radioisotope, 2021-2034
10.2.5. Europe Radiopharmaceutical CDMO/CMO Services Market revenue (US$ Million) estimates and forecasts By Therapeutic Area, 2021-2034
10.2.6. Europe Radiopharmaceutical CDMO/CMO Services Market revenue (US$ Million) estimates and forecasts by Country, 2021-2034
10.2.6.1. Germany
10.2.6.2. Denmark
10.2.6.3. Turkey
10.2.6.4. Romania
10.2.6.5. Bulgaria
10.2.6.6. Austria
10.2.6.7. Norway
10.2.6.8. Rest of Europe
10.3. Asia Pacific
10.3.1. Asia Pacific Radiopharmaceutical CDMO/CMO Services Market revenue (US$ Million) estimates and forecasts By Manufacturing Source, 2021-2034
10.3.2. Asia Pacific Radiopharmaceutical CDMO/CMO Services Market revenue (US$ Million) estimates and forecasts By Application, 2021-2034
10.3.3. Asia Pacific Radiopharmaceutical CDMO/CMO Services Market revenue (US$ Million) estimates and forecasts By Operation Scale, 2021-2034
10.3.4. Asia Pacific Radiopharmaceutical CDMO/CMO Services Market revenue (US$ Million) estimates and forecasts By Radioisotope, 2021-2034
10.3.5. Asia Pacific Radiopharmaceutical CDMO/CMO Services Market revenue (US$ Million) estimates and forecasts By Therapeutic Area, 2021-2034
10.3.6. Asia Pacific Radiopharmaceutical CDMO/CMO Services Market revenue (US$ Million) estimates and forecasts by Country, 2021-2034
10.3.6.1. China
10.3.6.2. Australia
10.3.6.3. Taiwan
10.3.6.4. South Korea
10.3.6.5. Thailand
10.3.6.6. Rest of Asia Pacific
10.4. Latin America
10.4.1. Latin America Radiopharmaceutical CDMO/CMO Services Market revenue (US$ Million) estimates and forecasts By Manufacturing Source, (US$ Million) 2021-2034
10.4.2. Latin America Radiopharmaceutical CDMO/CMO Services Market revenue (US$ Million) estimates and forecasts By Application, (US$ Million) 2021-2034
10.4.3. Latin America Radiopharmaceutical CDMO/CMO Services Market revenue (US$ Million) estimates and forecasts By Operation Scale, 2021-2034
10.4.4. Latin America Radiopharmaceutical CDMO/CMO Services Market revenue (US$ Million) estimates and forecasts By Radioisotope, 2021-2034
10.4.5. Latin America Radiopharmaceutical CDMO/CMO Services Market revenue (US$ Million) estimates and forecasts By Therapeutic Area, 2021-2034
10.4.6. Latin America Radiopharmaceutical CDMO/CMO Services Market revenue (US$ Million) estimates and forecasts by Country, 2021-2034
10.4.6.1. Brazil
10.4.6.2. Rest of Latin America
10.5. Middle East & Africa
10.5.1. Middle East & Africa Radiopharmaceutical CDMO/CMO Services Market revenue (US$ Million) estimates and forecasts By Manufacturing Source, (US$ Million) 2021-2034
10.5.2. Middle East & Africa Radiopharmaceutical CDMO/CMO Services Market revenue (US$ Million) estimates and forecasts By Application, (US$ Million) 2021-2034
10.5.3. Middle East & Africa Radiopharmaceutical CDMO/CMO Services Market revenue (US$ Million) estimates and forecasts By Operation Scale, 2021-2034
10.5.4. Middle East & Africa Radiopharmaceutical CDMO/CMO Services Market revenue (US$ Million) estimates and forecasts By Radioisotope, 2021-2034
10.5.5. Middle East & Africa Radiopharmaceutical CDMO/CMO Services Market revenue (US$ Million) estimates and forecasts By Therapeutic Area, 2021-2034
10.5.6. Middle East & Africa Radiopharmaceutical CDMO/CMO Services Market revenue (US$ Million) estimates and forecasts by Country, 2021-2034
10.5.6.1. Kuwait
10.5.6.2. U.A.E.
10.5.6.3. Egypt
10.5.6.4. Rest of MEA
Chapter 11. Competitive Landscape
11.1. Major Mergers and Acquisitions/Strategic Alliances
11.2. Company Profiles
11.2.1. Minerva Imaging
11.2.2. Evergreen Theragnostics, Inc.
11.2.3. NMR (NorthStar Medical Radioisotopes)
11.2.4. PharmaLogic
11.2.5. Eckert & Ziegler
11.2.6. AtomVie
11.2.7. Eczacıbaşı-Monrol
11.2.8. Cardinal Health
11.2.9. Nucleus RadioPharma
11.2.10. Seibersdorf Labor GmbH
11.2.11. Global Medical Solutions
11.2.12. SOFIE
11.2.13. SpectronRx
11.2.14. Agilera Pharma AS
11.2.15. Siemens Healthineers
11.2.16. Almac Group
11.2.17. Medi-Radiopharma
11.2.18. Itm Radiopharma
11.2.19. Nihon Medi-Physics Co., Ltd.
11.2.20. IONETIX Corporation
11.2.21. GBI
11.2.22. DuchemBio, Co., Ltd.
11.2.23. Grupo RPH
11.2.24. Other Prominent Players
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們